Detecting an overall survival benefit that is derived from progression-free survival.
暂无分享,去创建一个
[1] D. Sargent,et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Buyse,et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Junichi Sakamoto,et al. Exploring and validating surrogate endpoints in colorectal cancer , 2008, Lifetime data analysis.
[4] P. Barrett-Lee,et al. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer , 2005, British Journal of Cancer.
[5] Katherine S Panageas,et al. When you look matters: the effect of assessment schedule on progression-free survival. , 2007, Journal of the National Cancer Institute.
[6] R. Lilford,et al. The relationship between progression-free and post-progression survival in treating four types of metastatic cancer. , 2008, Cancer letters.
[7] Rajeshwari Sridhara,et al. Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues , 2008, Statistical methods in medical research.
[8] M. Buyse,et al. Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: Evidence from a pooled analysis of 2,838 patients randomized in 7 trials , 2008 .
[9] Malorye Allison. Trouble at the office , 2008, Nature Biotechnology.
[10] L. Siu,et al. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.